TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

25. 7.80 Panackal AA et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006;44:1740-3. 7.81 Leroy O et al. Epidemiology, management and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009;37:1612-8. 7.82 Viscoli C et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-9. 7.83 Kartsonis N et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005;49:3616-23. 7.84 Pappas PG et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:505-35. 7.85 Magill SS et al. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006;44:529-35. 7.86 Spellberg BJ et al. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42:244-51. 7.87 Kohli R et al. Fungal arthritis and osteomyelitis. Infect Dis Clin North Am 2005;19:831-51. 7.88 Smith PB et al. Neonatal candidiasis. Infect Dis Clin North Am 2005;19:603-15. 7.89 Fichtenbaum CJ et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000;30:749-56. 7.90 Saag MS et al. Treatment of fluconazole refractory oropharyngeal candidiasis with itraconazole oral solution in HIV positive patients. AIDS Res Hum Retroviruses 1999;15:1413-7. 7.91 Ally R et al. A randomized, double blind, double dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-54. 7.92 Gaitán-Cepeda LA et al. Oral candidosis as a clinical marker of immune failure in patients with HIV/ AIDS on HAART. AIDS Patient Care STDs 2005;19:70-7. 7.93 Epstein JB. Mucositis in the cancer patient and the immunosuppressed host. Infect Dis Clin North Am 2007;21:503-22. 7.94 Sobel JD et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004;351:876-83. 7.95 Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin North Am 2008;22:637- 52. 7.96 Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2006. Morb Mortal Wkly Rep 2006;55(RR-11):1-94. 7.97 Say PJ et al. Difficult to manage vaginitis. Clin Obstet Gynecol 2005;48:753-68. 7.98 Sobel JD. Vulvovaginal candidosis. Lancet 2007;369:1961-71. 7.99 Eckert LO. Acute vulvovaginitis. N Engl J Med 2006;355:1244-52. 7.100 Spence D et al. Vaginal discharge. Br Med J 2007;335:1147-51. 7.101 Bassetti M et al. Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev Anti Infect Ther 2006;4:875-85. 7.102 Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006;20:485-506. 7.103 Deck DH et al. Pharmacological advances in the treatment of invasive candidiasis. Expert Rev Anti Infect Ther 2006;4:137-49. 7.104 Spellberg BJ et al. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42:244-51. 7.105 Ásmundsdóttir LR et al. Improving survival of patients with candidaemia: analysis of prognostic factors from a long term, nationwide study in Iceland. Scand J Infect Dis 2005;37:111-20. 7.106 Almirante B et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005;43:1829-35. 7.107 Ito JI et al. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis 2005; 40(suppl. 6):S384-91. 7.108 Blyth CC et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009;123:1360-8. 7.109 Gafter-Gvili A et al. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008;83:1011-21. 7.110 Morrell M et al. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5. 7.111 Garey KW et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31. 7.112 Charlier C et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410. 7.113 Ruan SY et al. Candida glabrata fungaemia in intensive care units. Clin Microbiol Infect 2008;14: 136-40. 7.114 Betts RF et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009;48:1676-84. 7.115 Zaoutis TE et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009;123:877-94. 7.116 Reboli AC et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356: 2472-82. 7.117 Mora-Duarte J et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9. 7.118 Bennett JE. Echinocandins for candidemia in patients without neutropenia. N Engl J Med 2006;355: 1154-9. 7.119 Kullberg BJ et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non neutropenic patients: a randomised non inferiority trial. Lancet 2005;366:1435-42. 7.120 Nucci M et al. Should vascular catheters be removed from all patients with candidemia? An evidence based review. Clin Infect Dis 2002;34:591-9.
7.121 Walsh TJ et al. All catheter related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002;34:600-2. 7.122 Kojic EM et al. Candida infections of medical devices. Clin Microbiol Rev 2004;17:255-67. 7.123 Rodriguez D et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 2007;13:788-93. 7.124 Pascual A et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11. 7.125 Lewis JS. Therapeutic drug monitoring of antifungal agents. Curr Fungal Infect Rep 2009;3:96-102. 7.126 Trifilio S et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109:1532-5. 7.127 Pierrotti LC et al. Fungal endocarditis, 1995-2000. Chest 2002;122:302-10. 7.128 Johnston PG et al. Late recurrent Candida endocarditis. Chest 1991:99:1531-3. 7.129 Muehrcke DD et al. Surgical and long term antifungal therapy for fungal prosthetic valve endocarditis. Ann Thorac Surg 1995;60:538-43. 7.130 Cornely OA et al. Caspofungin fot the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007;60:363-9. 7.131 Jiménez-Expósito MJ et al. Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis 2004;39:e70-3. 7.132 Rajendram R et al. Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement. Clin Infect Dis 2005;40:e72-4. 7.133 Ellis ME et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50-62. 7.134 Keynan Y et al. Fungal endocarditis. Curr Fungal Infect Rep 2007;1:25-32. 7.135 Baddley JW et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008;27:519-29. 7.136 Zaoutis TE et al. Risk factors for disseminated candidiasis in children with candidaemia. Pediatr Infect Dis J 2004;23:635-41. 7.137 Martίnez-Vázquez C et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998;27:1130-3. 7.138 Breit SM et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005;139:135-40. 7.139 Darling K et al. Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid complex (ABLC). J Infect 2000;40:92-4. 7.140 Martίnez-Vázquez C et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998;27:1130-3. 7.141 Akler ME et al. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995; 20:657-64. 7.142 Sallam A et al. Endogenous Candida endophthalmitis. Expert Rev Anti Infect Ther 2006;4:675-85. 7.143 Shah CP et al. Ocular candidiasis: a review. Br J Ophthalmol 2008;92:466-8. 7.144 Wang AY et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9year experience of fungal peritonitis in a single center. Am J Kidney Dis 2000;36:1183-92. 7.145 Piraino B et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005;25:107-31. 7.146 Drew RH et al. Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis 2005;40:1465-70. 7.147 Sobel JD et al. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 2007;44: e46-9. 7.148 Kauffman CA et al. Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000;30:14-8. 7.149 Malani AN et al. Candida urinary tract infections: treatment options. Expert Rev Anti Infect Ther 2007;5:277-84. 7.150 Lundstrom T et al. Nosocomial candiduria: a review. Clin Infect Dis 2001;32:1602-7. 7.151 Kauffman CA. Candiduria. Clin Infect Dis 2005;41(suppl. 6):S371-6. 7.152 Achkar JM et al. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010;23:376-81. 7.153 Ameen M. Chromoblastomycosis: clinical presentation and management. Clin Exp Dermatol 2009; 34:849-54. 7.154 Pang KR et al. Subcutaneous fungal infections. Dermatol Ther 2004;17:523-31. 7.155 Minotto R et al. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. J Am Acad Dermatol 2001;44:585-92. 7.156 Parish JM et al. Coccidoidomycosis. Mayo Clin Proc 2008;83:343-9. 7.157 Saubolle MA et al. Epidemiological, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol 2007;45:26-30. 7.158 Anstead GM et al. Coccidioidomycosis. Infect Dis Clin North Am 2006;20:621-43. 7.159 Galgiani JN et al. Coccidioidomycosis. Clin Infect Dis 2005;41:1217-23. 7.160 Blair JE et al. Coccidioidomycosis in elderly persons. Clin Infect Dis 2008;47:1513-8. 7.161 Chiller TM et al. Coccidioidomycosis. Infect Dis Clin North Am 2003;17:41-57. 7.162 Valdivia L et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis 2006;12:958-62. 7.163 Masannat FY et al. Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy. Clin Infect Dis 2010;50:1-7. 7.164 Blair JE et al. Coccidioidomycosis in patients with hematologic malignancies. Arch Intern Med 2005; 165:113-7. 7.165 Bergstrom L et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum 2004;50:1959-66. 7.166 Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Curr Opin Infect Dis 2008;21:415-20. 7.167 Blair JE et al. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001;33:1536-44. 7.168 Braddy CM et al. Coccidioidomycosis after renal transplantation in an endemic area. Am J Transplant 2006;6:340-5. 7.169 Adam RD et al. The spectrum and presentation of disseminated coccidioidomycosis. Am J Med 2009;122:770-7. 7.170 Galgiani JN et al. Comparison of oral fluconazole and itraconazole for progressive, non meningeal coccidioidomycosis. A randomized, double blind trial. Ann Intern Med 2000;133:676-86.
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5 and 6: of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47: 7.38 Meersseman W et al. Invasive a
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98: product characteristics. Available
Page 99 and 100:
mortality after kidney transplantat
Page 101 and 102:
33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?